ZA986971B - 4-Aminopyrrole (3,2-D) pyrimidines as neuropeptide Y receptor antagonists. - Google Patents
4-Aminopyrrole (3,2-D) pyrimidines as neuropeptide Y receptor antagonists.Info
- Publication number
- ZA986971B ZA986971B ZA9806971A ZA986971A ZA986971B ZA 986971 B ZA986971 B ZA 986971B ZA 9806971 A ZA9806971 A ZA 9806971A ZA 986971 A ZA986971 A ZA 986971A ZA 986971 B ZA986971 B ZA 986971B
- Authority
- ZA
- South Africa
- Prior art keywords
- neuropeptide
- aminopyrrole
- pyrimidines
- receptor antagonists
- medicament
- Prior art date
Links
- WAUGGYPDCQZJKK-UHFFFAOYSA-N 1h-pyrrol-3-amine Chemical compound NC=1C=CNC=1 WAUGGYPDCQZJKK-UHFFFAOYSA-N 0.000 title 1
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 101710151321 Melanostatin Proteins 0.000 abstract 1
- 102400000064 Neuropeptide Y Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5530797P | 1997-08-05 | 1997-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA986971B true ZA986971B (en) | 2000-02-04 |
Family
ID=21997003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9806971A ZA986971B (en) | 1997-08-05 | 1998-08-04 | 4-Aminopyrrole (3,2-D) pyrimidines as neuropeptide Y receptor antagonists. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6040310A (de) |
| EP (1) | EP0896822B1 (de) |
| JP (1) | JP2978898B2 (de) |
| KR (1) | KR19990023355A (de) |
| AT (1) | ATE234098T1 (de) |
| AU (1) | AU726676B2 (de) |
| CA (1) | CA2244621C (de) |
| DE (1) | DE69812010T2 (de) |
| DK (1) | DK0896822T3 (de) |
| ES (1) | ES2191908T3 (de) |
| HU (1) | HUP9801792A3 (de) |
| IL (1) | IL125591A0 (de) |
| NZ (1) | NZ331233A (de) |
| PT (1) | PT896822E (de) |
| TW (1) | TW434015B (de) |
| ZA (1) | ZA986971B (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040254153A1 (en) * | 1999-11-08 | 2004-12-16 | Pfizer Inc | Compounds for the treatment of female sexual dysfunction |
| US20020091129A1 (en) * | 2000-11-20 | 2002-07-11 | Mitradev Boolell | Treatment of premature ejaculation |
| WO2002059310A2 (en) | 2000-12-12 | 2002-08-01 | University Of Connecticut | Polynucleotides encoding cellular transporters and methods of use thereof |
| US20030082647A1 (en) * | 2000-12-12 | 2003-05-01 | Reenan Robert A. | Transporter protein |
| US8129359B2 (en) | 2004-06-04 | 2012-03-06 | Ethicon, Inc. | Composition and method for treating post-surgical pain |
| US8377906B2 (en) | 2004-06-04 | 2013-02-19 | Ethicon, Inc. | Compositions and methods for preventing or reducing postoperative ileus and gastric stasis |
| WO2006108218A1 (en) * | 2005-04-15 | 2006-10-19 | Regenertech Pty Limited | Use of neuropeptide y (npy) and agonists and antagonists thereof for tissue regeneration |
| CN106188060A (zh) * | 2015-04-29 | 2016-12-07 | 厦门大学 | 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用 |
| CN107531710B (zh) * | 2015-08-13 | 2020-02-14 | 北京韩美药品有限公司 | Irak4抑制剂及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69216509T2 (de) * | 1991-08-12 | 1997-05-28 | Takeda Chemical Industries Ltd | Kondensierte Pyrimidinderivate, ihre Herstellung und ihre Verwendung als Antitumormittel |
| US6562862B1 (en) * | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| PL321136A1 (en) * | 1994-11-07 | 1997-11-24 | Pfizer | Some substituted derivatives of bencylamine as a new class of specific ligands of neuropeptide y1 |
| US5602024A (en) * | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
| EP0729758A3 (de) * | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidine und Pyrrolopyrimidine zur Behandlung von neuronalen und anderen Krankheiten |
| EP0759441A3 (de) * | 1995-06-30 | 1999-06-30 | Eli Lilly And Company | Verfahren zur Behandlung von mit Neuropeptid Y assozierten Zuständen |
-
1998
- 1998-07-27 EP EP98305963A patent/EP0896822B1/de not_active Expired - Lifetime
- 1998-07-27 ES ES98305963T patent/ES2191908T3/es not_active Expired - Lifetime
- 1998-07-27 PT PT98305963T patent/PT896822E/pt unknown
- 1998-07-27 AT AT98305963T patent/ATE234098T1/de not_active IP Right Cessation
- 1998-07-27 DE DE69812010T patent/DE69812010T2/de not_active Expired - Fee Related
- 1998-07-27 DK DK98305963T patent/DK0896822T3/da active
- 1998-07-29 US US09/124,025 patent/US6040310A/en not_active Expired - Fee Related
- 1998-07-30 IL IL12559198A patent/IL125591A0/xx unknown
- 1998-07-31 CA CA002244621A patent/CA2244621C/en not_active Expired - Fee Related
- 1998-07-31 TW TW087112649A patent/TW434015B/zh active
- 1998-08-03 AU AU78694/98A patent/AU726676B2/en not_active Ceased
- 1998-08-03 NZ NZ331233A patent/NZ331233A/xx unknown
- 1998-08-04 KR KR1019980031728A patent/KR19990023355A/ko not_active Ceased
- 1998-08-04 HU HU9801792A patent/HUP9801792A3/hu unknown
- 1998-08-04 ZA ZA9806971A patent/ZA986971B/xx unknown
- 1998-08-04 JP JP10220638A patent/JP2978898B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR19990023355A (ko) | 1999-03-25 |
| IL125591A0 (en) | 1999-03-12 |
| US6040310A (en) | 2000-03-21 |
| NZ331233A (en) | 2000-09-29 |
| HU9801792D0 (en) | 1998-09-28 |
| ATE234098T1 (de) | 2003-03-15 |
| JPH11130774A (ja) | 1999-05-18 |
| DE69812010T2 (de) | 2004-02-26 |
| DK0896822T3 (da) | 2003-06-02 |
| AU726676B2 (en) | 2000-11-16 |
| HUP9801792A2 (hu) | 2000-02-28 |
| CA2244621C (en) | 2003-07-29 |
| AU7869498A (en) | 1999-02-18 |
| DE69812010D1 (de) | 2003-04-17 |
| EP0896822A1 (de) | 1999-02-17 |
| TW434015B (en) | 2001-05-16 |
| EP0896822B1 (de) | 2003-03-12 |
| PT896822E (pt) | 2003-07-31 |
| HUP9801792A3 (en) | 2001-04-28 |
| ES2191908T3 (es) | 2003-09-16 |
| CA2244621A1 (en) | 1999-02-05 |
| JP2978898B2 (ja) | 1999-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997020823A3 (en) | 2-amino quinazoline derivatives as npy receptor antagonists | |
| NZ522326A (en) | Adenosine A2A receptor antagonists | |
| ZW9490A1 (en) | Imidazolyl-alkenoic acids | |
| CZ305838B6 (cs) | N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6 | |
| IL114894A (en) | Pyrrolidine derivatives as endothelin antagonists, pharmaceutical compositions containing them, and their use in the preparation of medicaments | |
| MY112102A (en) | Therapeutic heterocycles. | |
| CA2293621A1 (en) | 4-aminopyrrole(3,2-d) pyrimidines as neuropeptide y receptor antagonists | |
| WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
| EP0915094A4 (de) | Morphinanderivate und ihre medizinische Anwendung | |
| IL147977A0 (en) | Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain | |
| AU6564990A (en) | Substituted n-(imidazolyl)alkyl alanine derivatives | |
| GR3031215T3 (en) | Bicyclic heterocycles as neurokinin a antagonists | |
| HU9801792D0 (en) | 4-aminopyrrole(3,2-d)pyrimidines as neuropeptide y receptor antagonists | |
| AU2001263130A1 (en) | Bicyclic cyclohexylamines and their use as nmda receptor antagonists | |
| IL125982A0 (en) | 2-(arylphenyl) amino-imidazoline derivatives | |
| AU2002245005A1 (en) | Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor | |
| TWI255813B (en) | Compounds for use as alphavbeta3 receptor antagonists | |
| WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
| NZ504124A (en) | Phenyl-alkyl-imidazoles and use in treating inflammatory disease | |
| DE69627519D1 (de) | Sesquiterpen-derivate mit antiviraler aktivität | |
| WO2000007544A3 (en) | Vitronectin receptor antagonists | |
| ZA200000313B (en) | Neuropeptide Y antagonists. | |
| NZ516209A (en) | Indoloazepines as vasopressin receptor antagonists | |
| AU7962000A (en) | Us0027324for eating disorders | |
| SI1200402T1 (sl) | Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj |